SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001600132-23-000018
Filing Date
2023-03-06
Accepted
2023-03-06 08:30:49
Documents
17
Period of Report
2023-03-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K blph-20230303x8k.htm   iXBRL 8-K 52996
2 EX-4.1 blph-20230303xex4d1.htm EX-4.1 60946
3 EX-5.1 blph-20230303xex5d1.htm EX-5.1 12219
4 EX-10.1 blph-20230303xex10d1.htm EX-10.1 93792
5 GRAPHIC blph-20230303xex5d1001.jpg GRAPHIC 2128
6 GRAPHIC blph-20230303xex5d1002.jpg GRAPHIC 5394
  Complete submission text file 0001600132-23-000018.txt   395294

Data Files

Seq Description Document Type Size
7 EX-101.SCH blph-20230303.xsd EX-101.SCH 3141
8 EX-101.LAB blph-20230303_lab.xml EX-101.LAB 15266
9 EX-101.PRE blph-20230303_pre.xml EX-101.PRE 9668
11 EXTRACTED XBRL INSTANCE DOCUMENT blph-20230303x8k_htm.xml XML 4642
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

IRS No.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36845 | Film No.: 23707665
SIC: 2834 Pharmaceutical Preparations